ProKidney Corp/$PROK

1D1W1MYTD1Y5YMAX

About ProKidney Corp

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
Ticker
$PROK
Sector
Health
Primary listing
NASDAQ
Employees
231
Headquarters
Winston-Salem, United States
Website
prokidney.com

ProKidney Corp Metrics

BasicAdvanced
$371M
-
-$0.56
1.72
-

Bulls say / Bears say

ProKidney completed enrollment of patients for the PROACT 1 accelerated-approval efficacy analysis and remains on track to complete full enrollment in the second half of 2026, reducing a major near-term execution risk. (ProKidney)
The Phase 2 REGEN-007 findings received peer-reviewed publication in the Clinical Journal of the American Society of Nephrology in January 2026, providing external scientific validation of the program’s kidney-function data ahead of the pivotal readout. (CJASN/PMC)
The company reported $181.6 million in cash, cash equivalents and marketable securities at June 30, 2026, which management expects to support operations into mid-2027—covering the planned Q2 2027 accelerated-approval efficacy readout. (ProKidney)
PROK remains dependent on a single clinical program, and its Phase 3 accelerated-approval efficacy readout is not expected until Q2 2027; the larger confirmatory endpoint is not expected until the second half of 2029, extending regulatory and execution risk. (ProKidney)
Liquidity is declining while spending rises: cash, cash equivalents and marketable securities fell to $181.6 million at June 30, 2026 from $224.9 million three months earlier, while first-half operating cash burn reached $82.1 million. This raises the risk of future equity financing and dilution before commercial revenue. (ProKidney)
The Phase 3 outcome remains uncertain despite encouraging earlier data: ProKidney states that early-stage results may not predict Phase 3 success, and its personalized autologous therapy introduces manufacturing, logistics, chain-of-custody and regulatory complexities. (SEC Form 10-K)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.

ProKidney Corp News

AllArticlesVideos

20 stocks likely to lose money even if the bull market continues

Market Watch4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.